The pangenotypic direct-acting antivirals (DAAs) glecaprevir (developed by AbbVie and Enanta) coformulated with pibrentasvir (G/P) are approved as an 8-week regimen to treat chronic HCV infection for all six major genotypes (GT). Historically, an on-treatment predictor of HCV cure with interferon (IFN)-containing regimens has been viral suppression at treatment week 4. However, the relevance of viral kinetics as predictors of cure in the era of shortened, 8-week DAA regimens is unclear, and concerns remain that failure to suppress HCV RNA quickly may lead to relapse. An integrated analysis of patients treated with G/P for 8 weeks was performed to investigate factors impacting time to viral suppression, and whether lack of viral suppression by treatment week 4 was predictive of relapse.